- Home
- IPST vs TCRX Comparison
IPST vs TCRX Comparison
Compare IPST & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPST
- TCRX
- Stock Information
- Founded
- IPST 2011
- TCRX 2018
- Country
- IPST United States
- TCRX United States
- Employees
- IPST N/A
- TCRX N/A
- Industry
- IPST Beverages (Production/Distribution)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- IPST Consumer Staples
- TCRX Health Care
- Exchange
- IPST Nasdaq
- TCRX Nasdaq
- Market Cap
- IPST 163.4M
- TCRX 140.7M
- IPO Year
- IPST 2024
- TCRX 2021
- Fundamental
- Price
- IPST $15.00
- TCRX $1.13
- Analyst Decision
- IPST
- TCRX Strong Buy
- Analyst Count
- IPST 0
- TCRX 7
- Target Price
- IPST N/A
- TCRX $8.50
- AVG Volume (30 Days)
- IPST 40.6K
- TCRX 939.6K
- Earning Date
- IPST 11-14-2025
- TCRX 11-12-2025
- Dividend Yield
- IPST N/A
- TCRX N/A
- EPS Growth
- IPST N/A
- TCRX N/A
- EPS
- IPST N/A
- TCRX N/A
- Revenue
- IPST $7,058,550.00
- TCRX $8,423,000.00
- Revenue This Year
- IPST N/A
- TCRX $255.18
- Revenue Next Year
- IPST N/A
- TCRX N/A
- P/E Ratio
- IPST N/A
- TCRX N/A
- Revenue Growth
- IPST N/A
- TCRX N/A
- 52 Week Low
- IPST $5.31
- TCRX $1.02
- 52 Week High
- IPST $80.00
- TCRX $5.56
- Technical
- Relative Strength Index (RSI)
- IPST N/A
- TCRX 29.85
- Support Level
- IPST N/A
- TCRX $1.02
- Resistance Level
- IPST N/A
- TCRX $1.25
- Average True Range (ATR)
- IPST 0.00
- TCRX 0.16
- MACD
- IPST 0.00
- TCRX -0.07
- Stochastic Oscillator
- IPST 0.00
- TCRX 7.81
About IPST Heritage Distilling Holding Company Inc. Common Stock
Heritage Distilling Holding Co Inc is a craft distiller producing, marketing, and selling a diverse line of award-winning craft spirits, including whiskeys, vodkas, gins, rums, and ready-to-drink canned cocktails. The company sells its products through wholesale distribution, directly to consumers through its owned and operated distilleries and tasting rooms located in Washington and Oregon, and by shipping directly to consumers online, where legal. Currently, it sells products in the Pacific Northwest with limited distribution in other states throughout the U.S.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.